1cP-MiPLA
1cP-MiPLA is a 1-cyclopropanoyl prodrug of MiPLA, combining the 1-acyl prodrug strategy of 1cP-LSD with the milder MiPLA parent. It is presumed to hydrolyse to MiPLA in the body and is essentially uncharacterised outside user reports.
01 Overview
1cP-MiPLA appeared on the research-chemical market as a legal-workaround lysergamide, stacking two design ideas: the N1-cyclopropanoyl group used to evade prodrug-specific bans, and the reduced-potency MiPLA base. It is sold as blotter.
Because it is assumed to be cleaved to MiPLA, its expected experience is MiPLA-like: an LSD-type psychedelic that is somewhat milder and less potent. There is no clinical or formal pharmacological data on 1cP-MiPLA itself; everything is inference and anecdote.
02 Mechanism
Presumed prodrug hydrolysed in vivo to MiPLA, a partial agonist at 5-HT2A and related serotonin receptors.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 15–30 mcg | Sublingual | Microdose range. |
| Common | 100–200 mcg | Sublingual | Full psychedelic dose; MiPLA-like, less potent than LSD. |
| Strong | 200–350 mcg | Oral | Strong experience. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Psychedelic visualsColour and geometric visuals, reported as milder MiPLA-like. | 5-8 h | Anecdotal | |
| Mood elevationEuphoria and emotional openness. | Anecdotal | ||
| Anxiety at high dosesParanoia or overwhelm possible at strong doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Sympathomimetic effectsRaised heart rate and blood pressure, mydriasis and tremor. | Mild | Common | Anecdotal | |
| Acute psychological distressAnxiety, paranoia or a difficult experience during acute effects. | Moderate | Common | Anecdotal | |
| Persistent perceptual changes (HPPD)Lasting visual disturbances after use. | Moderate | Rare | Observational |